AF
FULC icon

Amalgamated Financial’s Fulcrum Therapeutics FULC Stock Holding History

Amalgamated Financial’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$79K Buy
+3,324
New +$47K ﹤0.01% 2241

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Financial's FULC Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Fulcrum Therapeutics (FULC) in Q1 2022: 3,324 shares worth $79K. The stake represents ﹤0.01% of the portfolio and ranks #2241 among its holdings.

108 funds tracked by Wall St. Rank hold FULC as of Q1 2022.

  • Amalgamated Financial held 3,324 shares of Fulcrum Therapeutics worth $79K as of Q1 2022.
  • Fulcrum Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Fulcrum Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2241 holding.
  • 108 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.